D.C. Rijken

9.2k citations

134 papers · 7.3k indexed · 2 hit papers · h-index 45

Impact in

Hematology top 0.1%
- Blood Coagulation and Thrombosis Mechanisms
Cancer Research top 0.2%
- Protease and Inhibitor Mechanisms

Papers in

Hematology 71
- Blood Coagulation and Thrombosis Mechanisms 63
- Platelet Disorders and Treatments 10
Cancer Research 80
- Protease and Inhibitor Mechanisms 80

Co-authors: Désiré Collen Marc Hoylaerts D Collen H.R. Lijnen G. Wijngaards Dmitry V. Sakharov Frank W.G. Leebeek Osamu Matsuo
Journals: Thrombosis and Haemostasis (22 papers)Journal of Thrombosis and Haemostasis (12 papers)Journal of Biological Chemistry (11 papers)Thrombosis Research (10 papers)European Journal of Biochemistry (5 papers)
Partner nations: Netherlands Belgium United Kingdom

In The Last Decade

D.C. Rijken

132 papers receiving 6.6k citations

Hit Papers

align trajectories log scale

Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. 1982 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1982 Journal of Biological Chemistry
1981 Journal of Biological Chemistry

Peers

Countries citing papers authored by D.C. Rijken

Since Specialization

Citations

This map shows the geographic impact of D.C. Rijken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.C. Rijken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.C. Rijken more than expected).

Fields of papers citing papers by D.C. Rijken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.C. Rijken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.C. Rijken. The network helps show where D.C. Rijken may publish in the future.

Co-authorship network

The 25 scholars most cited alongside D.C. Rijken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D.C. Rijken Line = papers co-authored together D.C. Rijken links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Levels of Fibrinogen Variants Are Altered in Severe COVID-19 SHILAP Revista de lepidopterología ·Stanford Prochaska, S. Lüpfert, Traian Barbu, Casper Rokx, Els van Nood, Eric C. M. Van Gorp, Marco Goeijenbier, Johannes P. C. van den Akker, Henrik Endeman, D.C. Rijken, Marieke J.H.A. Kruip, Susan Mathew Ann, J. Koopman, Moniek P.M. de Maat	2023	5
2	Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID‐19, not entirely explaining the increased risk of thrombosis Journal of Thrombosis and Haemostasis ·Stanford Prochaska, S. Lüpfert, Lotte Geers, Johan A. Slotman, Phil Burger, Coen Maas, Hannelore I. Bax, Jelle Miedema, Eric C. M. Van Gorp, Marco Goeijenbier, Johannes P. C. van den Akker, Henrik Endeman, D.C. Rijken, Marieke J. H. A. Kruip, Moniek P.M. de Maat	2022	10
3	Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII Journal of Thrombosis and Haemostasis ·D.C. Rijken, T. Sugano, Creed McCaslin, Frank W.G. Leebeek, Shirley Uitte de Willige	2016	43
4	Identification of Fibrin Clot-Bound Plasma Proteins PLoS ONE ·A.A. Ilinsky, Frank W.G. Leebeek, Jeroen Demmers, D.C. Rijken	2012	48
5	Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests Journal of Thrombosis and Haemostasis ·D.C. Rijken, Schulz Birte, Ana H.C. Guimarães, A.A. Ilinsky, Sarwa Darwish Murad, Harry L.A. Janssen, Frank W.G. Leebeek	2012	60
6	Plasma Clot Lysis Time and Its Association with Cardiovascular Risk Factors in Black Africans PLoS ONE ·Zelda de Lange, Marlien Pieters, Johann C. Jerling, Annamarie Kruger, D.C. Rijken	2012	21
7	High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease Thrombosis Research ·Emile L.E. de Bruijne, Ann Gils, D.C. Rijken, A.V. Ryabov, Ana H.C. Guimarães, Don Poldermans, Paul Declerck, Frank W.G. Leebeek	2010	15
8	Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children Journal of Thrombosis and Haemostasis ·Marieke Emonts, Emile L.E. de Bruijne, Ana H.C. Guimarães, Paul Declerck, Frank W.G. Leebeek, M.P.M. De Maat, D.C. Rijken, Jan A. Hazelzet, Ann Gils	2008	33
9	Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot Biochemical and Biophysical Research Communications ·D.C. Rijken, Katoo Shuuichi, Theo M. Luider, Frank W.G. Leebeek	2006	35
10	High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke Journal of Thrombosis and Haemostasis ·Frank W.G. Leebeek, M.P.J. van Goor, Ana H.C. Guimarães, 郑黎丽, M.P.M. De Maat, Diederik W.J. Dippel, D.C. Rijken	2005	85
11	The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models Ultrasound in Medicine & Biology ·Marlien Pieters, R.T. Hekkenberg, Marrie Barrett-Bergshoeff, D.C. Rijken	2004	24
12	Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays British Journal of Haematology ·Ana H.C. Guimarães, Nico H. van Tilburg, Hans L. Vos, R M Bertina, D.C. Rijken	2004	39
13	Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2tu-PA) Thrombosis and Haemostasis ·Marrie Barrett-Bergshoeff, A.F.H. Jie, Marco Criscuoli, M. Demello, D.C. Rijken	2003	15
14	Basic Principles in Thrombolysis: Regulatory Role of Plasminogen Thrombosis Research ·D.C. Rijken, D.V. Sakharov	2001	60
15	Identification of the epidermal growth factor‐like domains of thrombomodulin essential for the acceleration of thrombin‐mediated inactivation of single‐chain urokinase‐type plasminogen activator European Journal of Biochemistry ·Kun-peng, John Morser, D.C. Rijken	2001	11
16	Acceleration of Fibrinolysis by High-frequency Ultrasound Thrombosis Research ·Dmitry V. Sakharov, R.T. Hekkenberg, D.C. Rijken	2000	81
17	Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects Journal of Laboratory and Clinical Medicine ·SA Honda, Marcel Levi, D S Sutarto, F. Haverkate, Michael R. Lassen, A.V. Ryabov, D.C. Rijken	1999	9
18	On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B Journal of Biological Chemistry ·Dmitry V. Sakharov, Edward F. Plow, D.C. Rijken	1997	171
19	Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects Clinical Pharmacology & Therapeutics ·P. Tanswell, E. Seifried, Anusha Karve, Werner Feuerer, D.C. Rijken	1989	64
20	Plasminogen activator inhibitor 1 (PAI-1) antigen levels in human plasma samples TNO Repository ·D.C. Rijken, (unknown), Наталя Рудакова, (unknown), (unknown)	1988	8

About D.C. Rijken

D.C. Rijken is a scholar working on Hematology, Cancer Research, Internal Medicine, Biotechnology and Immunology and Allergy, having authored 134 papers that have together received 7.3k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (80 papers), Blood Coagulation and Thrombosis Mechanisms (63 papers), Blood properties and coagulation (45 papers), Enzyme Production and Characterization (13 papers), Venous Thromboembolism Diagnosis and Management (10 papers), Platelet Disorders and Treatments (10 papers), Peptidase Inhibition and Analysis (9 papers) and Signaling Pathways in Disease (9 papers). The work is most often cited by research in Hematology (3.3k citations), Cancer Research (3.4k citations), Internal Medicine (710 citations), Immunology and Allergy (571 citations) and Biotechnology (741 citations). D.C. Rijken has collaborated with scholars based in Netherlands, Belgium and United Kingdom. Frequent co-authors include Désiré Collen, Marc Hoylaerts, D Collen, H.R. Lijnen, G. Wijngaards, Dmitry V. Sakharov, Frank W.G. Leebeek, Désiré Collen, Osamu Matsuo and Marrie Barrett-Bergshoeff. Their work appears in journals such as Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, Journal of Biological Chemistry, Thrombosis Research and European Journal of Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact